Hemogenyx Pharmaceuticals plc (LSE: HEMO), the London-headquartered clinical-stage biopharmaceutical group, has announced that its Chairman, Professor Sir Marc Feldmann, has been awarded the Robert Koch Medal in Gold by the Robert Koch Foundation. The medal, presented at a ceremony at the Robert Koch Institute in Berlin on 13 November 2026, recognises Sir Marc's lifetime achievement in immunology. The award highlights his foundational role in developing anti-TNF therapy — now a global standard of care — and may reinforce investor confidence in the scientific leadership guiding Hemogenyx's clinical programmes.
Key Points
- Hemogenyx Pharmaceuticals plc (LSE: HEMO) — clinical-stage biopharmaceutical group developing therapies for blood and autoimmune diseases
- Chairman Professor Sir Marc Feldmann awarded the Robert Koch Medal in Gold by the Robert Koch Foundation on 13 November 2026
- Sir Marc was knighted in 2010 and co-received the 2003 Albert Lasker Award for Clinical Medical Research for his work on anti-TNF therapy
- Investors may watch how Sir Marc's scientific profile supports Hemogenyx's ongoing clinical programmes, including lead programme HG-CT-1
Sir Marc Feldmann's TNF Research and the Birth of Biological Therapy for Autoimmune Disease
The Robert Koch Foundation's award citation highlights Sir Marc's pioneering research at the Kennedy Institute of Rheumatology, University of Oxford, where, working alongside rheumatologist Professor Sir Ravinder N. Maini in the 1980s, he proposed that tumour necrosis factor (TNF) plays a central role in rheumatoid arthritis. The two scientists subsequently devised methods to test this hypothesis and demonstrated that blocking TNF effectively alters the course of the disease. Anti-TNF treatment became the first biological therapy to deliver significant improvement in an autoimmune disease and is now used by millions of patients worldwide as a standard of care.
Monoclonal Antibodies, Biosimilars and Wider Impact on Modern Medicine
Beyond rheumatoid arthritis, the Robert Koch Foundation noted that Sir Marc's work helped shape the development and clinical use of monoclonal antibodies as a therapeutic class, as well as the biosimilars that followed. His contributions were recognised when Queen Elizabeth II knighted him in 2010 for services to medicine, particularly anti-TNF therapy. Together with Sir Ravinder, he has received numerous international awards, including the 2003 Albert Lasker Award for Clinical Medical Research, regarded as one of the most prestigious honours in biomedical science. The announcement states he continues to focus on translational research and supporting young scientists.
Hemogenyx's Clinical Pipeline and the Role of Scientific Leadership
Hemogenyx Pharmaceuticals operates research facilities in New York City through its US subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC. The company's lead programme, HG-CT-1, is a CAR-T cell therapy currently in a Phase 1 clinical trial for relapsed or refractory acute myeloid leukaemia. CEO and Co-Founder Dr Vladislav Sandler stated in the announcement that Sir Marc's scientific judgement and translational experience continue to guide the company as it advances its clinical programmes. The Robert Koch Medal in Gold honours a scientist's outstanding life's work and is distinct from the Foundation's Robert Koch Prize, which carries a €120,000 endowment.



Please wait processing your request...